Trial Profile
A Study to Compare the Medication Persistence and Discontinuation of Rivaroxaban and Dabigatran Among Patients With Non Valvular Atrial Fibrillation in Real World
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jun 2016
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Embolism and thrombosis
- Focus Therapeutic Use
- 10 Jun 2016 New trial record